Patrick Rozenberg

Patrick Rozenberg

Auto-generated profile, based on publicly available information

Patrick Rozenberg

Department of Obstetrics and Gynecology American Hospital of Paris Neuilly‐sur‐Seine France

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
LSLoic SENTILHES
Loic SENTILHES
ASAurélien Seco
Aurélien Seco
EAElie Azria
Elie Azria
GBGaël Beucher
Gaël Beucher
MBMarie-Pierre Bonnet
Marie-Pierre Bonnet
JSJustine Schwanka
Justine Schwanka

30 September 2015 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
JTJulie Tort
Julie Tort
PRPatrick Rozenberg
Patrick Rozenberg
MTMamadou Traoré
Mamadou Traoré
PFPierre Fournier
Pierre Fournier
ADAlexandre Dumont
Alexandre Dumont
Postpartum hemorrhage (PPH) is the leading cause of maternal mortality in Sub-Saharan-Africa (SSA). Although clinical guidelines treating PPH are available, their implementation remains a great challenge in resource poor settings. A better understanding of the factors associated with PPH maternal mortality is critical for preventing risk of hospital-based maternal death. The purpose of this study was thus to assess which factors contribute to maternal death occurring during PPH. The factors were as follows: women’s characteristics, aspects of pregnancy and delivery; components of PPH management; and organizational characteristics of the referral hospitals in Senegal and Mali. A cross-sectional survey nested in a cluster randomized trial (QUARITE trial) was carried out in 46 referral hospitals during the pre-intervention period from October 2007 to September 2008 in Senegal and Mali. Individual and hospital characteristics data were collected through standardized questionnaires. A multivariable logistic mixed model was used to identify the factors that were significantly associated with PPH maternal death. Among the 3,278 women who experienced PPH, 178 (5.4 %) of them died before hospital discharge. The factors that were significantly associated with PPH maternal mortality were: age over 35 years (adjusted OR = 2.16 [1.26–3.72]), living in Mali (adjusted OR = 1.84 [1.13–3.00]), residing outside the region location of the hospital (adjusted OR = 2.43 [1.29–4.56]), pre-existing chronic disease before pregnancy (adjusted OR = 7.54 [2.54–22.44]), prepartum severe anemia (adjusted OR = 6.65 [3.77–11.74]), forceps or vacuum delivery (adjusted OR = 2.63 [1.19–5.81]), birth weight greater than 4000 grs (adjusted OR = 2.54 [1.26–5.10]), transfusion (adjusted OR = 2.17 [1.53–3.09]), transfer to another hospital (adjusted OR = 13.35 [6.20–28.76]). There was a smaller risk of PPH maternal death in hospitals with gynecologist-obstetrician (adjusted OR = 0.55 [0.35–0.89]) than those with only a general practitioner trained in emergency obstetric care (EmOC). Our findings may have direct implications for preventing PPH maternal death in resource poor settings. In particular, we suggest anemia should be diagnosed and treated before delivery and inter-hospital transfer of women should be improved, as well as the management of blood banks for a quicker access to transfusion. Finally, an extent training of general practitioners in EmOC would contribute to the decrease of PPH maternal mortality.

1 November 2006 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
PRPatrick Rozenberg
Patrick Rozenberg
LBLaurence Bussières
Laurence Bussières
SCSylvie Chevret
Sylvie Chevret
JBJean Pierre Bernard
Jean Pierre Bernard
LMLydia Malagrida
Lydia Malagrida
YVYves Ville
Yves Ville

1 September 2003 in Human Reproduction
Verified
Journal Article
Open access
PDF file
PRPatrick Rozenberg
Patrick Rozenberg
SCSylvie Chevret
Sylvie Chevret
ECEric Camus
Eric Camus
RTRenaud de Tayrac
Renaud de Tayrac
OGOlivier Garbin
Olivier Garbin
FGFor The Grog
For The Grog
BACKGROUND: Medical treatment of ectopic pregnancies is common. To increase the efficacy of methotrexate, the association of mifepristone has been proposed. METHODS: We performed a large prospective multicentre double‐blind sequential randomized trial in order to compare the efficacy of methotrexate and mifepristone (600 mg given orally) versus methotrexate and placebo. RESULTS: A total of 212 ectopic pregnancies was randomized. There was no significant difference in the initial characteristics between the two groups. There was no significant difference in the success rate of medical treatment between the methotrexate–mifepristone (n = 113) and the methotrexate–placebo group (n = 99): 79.6% (90/113) versus 74.2% (72/97) respectively, RR (95% CI): 1.07 (0.92–1.25), P = 0.41, non‐significant. However, there was a quantitative interaction between progesterone level and effect of treatment: when progesterone level was ≥10 ng/l, the efficacy of the combination of mifepristone and methotrexate was significantly higher than the combination of methotrexate and placebo, with an 83.3% success rate (15/18) versus 38.5% (5/13) respectively. CONCLUSIONS: Our study failed to demonstrate any benefit of the addition of mifepristone to methotrexate. By contrast, the quantitative interaction between treatment effect and baseline serum progesterone suggested that this combination could be limited to ectopic pregnancies associated with high serum progesterone concentrations.

1 March 2002 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
PDF file
PRP. Rozenberg
P. Rozenberg
AGA. Gillet
A. Gillet
YVY. Ville
Y. Ville

28 September 2015 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
PDF file
TPThomas Popowski
Thomas Popowski
RPRaphael Porcher
Raphael Porcher
JFJulie Fort
Julie Fort
SJSophie Javoise
Sophie Javoise
PRPatrick Rozenberg
Patrick Rozenberg